Global Dermatomyositis Treatment Market
Global Dermatomyositis Treatment Market

Dermatomyositis Treatment Comprehensive Study by Dermatomyositis Type (Classic Dermatomyositis (CDM), Amyopathic Dermatomyositis (ADM), Hypomyopathic Dermatomyositis (HDM), Other), Age Group (Children, Adults), Medication Type (Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent), Non-Pharmacotherapy (General Therapeutic Measures, Surgery)), End User (Hospitals, Research & Development Institutes, Other) Players and Region - Global Market Outlook to 2025

Dermatomyositis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

May 2020 Edition 227 Pages 213 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Dermatomyositis Treatment Market Overview:
Dermatomyositis (DM) is a rare autoimmune condition that affects children and adults and is one of the many idiopathic inflammatory myopathies (IIM) with cutaneous involvement (predominately affects the skin and muscles). Dermatomyositis may occur at any time from infancy through approximately age 80, but most commonly it occurs between ages 40 to 60. The estimated incidence of dermatomyositis is 9.63 cases per million people. In children, the symptoms usually appear between the ages of five to 15 years. Approximately three in 1,000,000 children are affected by juvenile dermatomyositis. Females are affected by dermatomyositis twice as often as males. The growing dermatomyositis cases worldwide has increased the demand for dermatomyositis treatment. Some of the key players profiled in the study are Ranbaxy Laboratories Limited (India), Abbott Laboratories (United States), Sanofi S.A. (France), Cipla Limited (India), Actelion Pharmaceuticals Ltd. (Switzerland) and Corbus Pharmaceuticals Holdings, Inc. (United States).

On the basis of geography, the market of Dermatomyositis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Dermatomyositis Type, the sub-segment i.e. Classic Dermatomyositis (CDM) will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Children will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medication Type, the sub-segment i.e. Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent) will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Dermatomyositis Cases Globally
  • Dermatomyositis Treatment Suitability for Patient of Any Age

Market Trend
  • Increasing Skin And Muscles Diseases Among Adults

Restraints
  • High Cost of Dermatomyositis Treatment

Opportunities
  • Regulatory Support for Dermatomyositis Treatment
  • Untapped Emerging Countries

Challenges
  • Limited Adoption in Undeveloped Areas




Target Audience:
New Entrants/Investors, Analysts and Strategic Business Planners, Dermatomyositis Treatment Provider, Healthcare Institutes, Venture Capitalists and Private Equity Firms and Government Regulatory and Research Organizations

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Dermatomyositis Treatment market on the basis of product [] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Dermatomyositis Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Dermatomyositis Treatment industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Dermatomyositis Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Dermatomyositis Type
  • Classic Dermatomyositis (CDM)
  • Amyopathic Dermatomyositis (ADM)
  • Hypomyopathic Dermatomyositis (HDM)
  • Other

By Age Group
  • Children
  • Adults

By Medication Type
  • Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent)
  • Non-Pharmacotherapy (General Therapeutic Measures, Surgery)

By End User
  • Hospitals
  • Research & Development Institutes
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Dermatomyositis Cases Globally
      • 3.2.2. Dermatomyositis Treatment Suitability for Patient of Any Age
    • 3.3. Market Challenges
      • 3.3.1. Limited Adoption in Undeveloped Areas
    • 3.4. Market Trends
      • 3.4.1. Increasing Skin And Muscles Diseases Among Adults
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dermatomyositis Treatment, by Dermatomyositis Type, Age Group, Medication Type, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Dermatomyositis Treatment (Value)
      • 5.2.1. Global Dermatomyositis Treatment by: Dermatomyositis Type (Value)
        • 5.2.1.1. Classic Dermatomyositis (CDM)
        • 5.2.1.2. Amyopathic Dermatomyositis (ADM)
        • 5.2.1.3. Hypomyopathic Dermatomyositis (HDM)
        • 5.2.1.4. Other
      • 5.2.2. Global Dermatomyositis Treatment by: Age Group (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Dermatomyositis Treatment by: Medication Type (Value)
        • 5.2.3.1. Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent)
        • 5.2.3.2. Non-Pharmacotherapy (General Therapeutic Measures, Surgery)
      • 5.2.4. Global Dermatomyositis Treatment by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Research & Development Institutes
        • 5.2.4.3. Other
      • 5.2.5. Global Dermatomyositis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dermatomyositis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ranbaxy Laboratories Limited (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cipla Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Actelion Pharmaceuticals Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Corbus Pharmaceuticals Holdings, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Dermatomyositis Treatment Sale, by Dermatomyositis Type, Age Group, Medication Type, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Dermatomyositis Treatment (Value)
      • 7.2.1. Global Dermatomyositis Treatment by: Dermatomyositis Type (Value)
        • 7.2.1.1. Classic Dermatomyositis (CDM)
        • 7.2.1.2. Amyopathic Dermatomyositis (ADM)
        • 7.2.1.3. Hypomyopathic Dermatomyositis (HDM)
        • 7.2.1.4. Other
      • 7.2.2. Global Dermatomyositis Treatment by: Age Group (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Dermatomyositis Treatment by: Medication Type (Value)
        • 7.2.3.1. Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent)
        • 7.2.3.2. Non-Pharmacotherapy (General Therapeutic Measures, Surgery)
      • 7.2.4. Global Dermatomyositis Treatment by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Research & Development Institutes
        • 7.2.4.3. Other
      • 7.2.5. Global Dermatomyositis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dermatomyositis Treatment: by Dermatomyositis Type(USD Million)
  • Table 2. Dermatomyositis Treatment Classic Dermatomyositis (CDM) , by Region USD Million (2014-2019)
  • Table 3. Dermatomyositis Treatment Amyopathic Dermatomyositis (ADM) , by Region USD Million (2014-2019)
  • Table 4. Dermatomyositis Treatment Hypomyopathic Dermatomyositis (HDM) , by Region USD Million (2014-2019)
  • Table 5. Dermatomyositis Treatment Other , by Region USD Million (2014-2019)
  • Table 6. Dermatomyositis Treatment: by Age Group(USD Million)
  • Table 7. Dermatomyositis Treatment Children , by Region USD Million (2014-2019)
  • Table 8. Dermatomyositis Treatment Adults , by Region USD Million (2014-2019)
  • Table 9. Dermatomyositis Treatment: by Medication Type(USD Million)
  • Table 10. Dermatomyositis Treatment Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent) , by Region USD Million (2014-2019)
  • Table 11. Dermatomyositis Treatment Non-Pharmacotherapy (General Therapeutic Measures, Surgery) , by Region USD Million (2014-2019)
  • Table 12. Dermatomyositis Treatment: by End User(USD Million)
  • Table 13. Dermatomyositis Treatment Hospitals , by Region USD Million (2014-2019)
  • Table 14. Dermatomyositis Treatment Research & Development Institutes , by Region USD Million (2014-2019)
  • Table 15. Dermatomyositis Treatment Other , by Region USD Million (2014-2019)
  • Table 16. South America Dermatomyositis Treatment, by Country USD Million (2014-2019)
  • Table 17. South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 18. South America Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 19. South America Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 20. South America Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 21. Brazil Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 22. Brazil Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 23. Brazil Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 24. Brazil Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 25. Argentina Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 26. Argentina Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 27. Argentina Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 28. Argentina Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 29. Rest of South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 30. Rest of South America Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 31. Rest of South America Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 32. Rest of South America Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 33. Asia Pacific Dermatomyositis Treatment, by Country USD Million (2014-2019)
  • Table 34. Asia Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 35. Asia Pacific Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 36. Asia Pacific Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 37. Asia Pacific Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 38. China Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 39. China Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 40. China Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 41. China Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 42. Japan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 43. Japan Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 44. Japan Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 45. Japan Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 46. India Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 47. India Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 48. India Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 49. India Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 50. South Korea Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 51. South Korea Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 52. South Korea Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 53. South Korea Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 54. Taiwan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 55. Taiwan Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 56. Taiwan Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 57. Taiwan Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 58. Australia Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 59. Australia Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 60. Australia Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 61. Australia Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 62. Rest of Asia-Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 66. Europe Dermatomyositis Treatment, by Country USD Million (2014-2019)
  • Table 67. Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 68. Europe Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 69. Europe Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 70. Europe Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 71. Germany Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 72. Germany Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 73. Germany Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 74. Germany Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 75. France Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 76. France Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 77. France Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 78. France Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 79. Italy Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 80. Italy Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 81. Italy Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 82. Italy Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 83. United Kingdom Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 84. United Kingdom Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 85. United Kingdom Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 86. United Kingdom Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 87. Netherlands Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 88. Netherlands Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 89. Netherlands Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 90. Netherlands Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 91. Rest of Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 92. Rest of Europe Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 93. Rest of Europe Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 94. Rest of Europe Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 95. MEA Dermatomyositis Treatment, by Country USD Million (2014-2019)
  • Table 96. MEA Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 97. MEA Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 98. MEA Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 99. MEA Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 100. Middle East Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 101. Middle East Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 102. Middle East Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 103. Middle East Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 104. Africa Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 105. Africa Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 106. Africa Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 107. Africa Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 108. North America Dermatomyositis Treatment, by Country USD Million (2014-2019)
  • Table 109. North America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 110. North America Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 111. North America Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 112. North America Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 113. United States Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 114. United States Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 115. United States Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 116. United States Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 117. Canada Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 118. Canada Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 119. Canada Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 120. Canada Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 121. Mexico Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2014-2019)
  • Table 122. Mexico Dermatomyositis Treatment, by Age Group USD Million (2014-2019)
  • Table 123. Mexico Dermatomyositis Treatment, by Medication Type USD Million (2014-2019)
  • Table 124. Mexico Dermatomyositis Treatment, by End User USD Million (2014-2019)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Dermatomyositis Treatment: by Dermatomyositis Type(USD Million)
  • Table 132. Dermatomyositis Treatment Classic Dermatomyositis (CDM) , by Region USD Million (2020-2025)
  • Table 133. Dermatomyositis Treatment Amyopathic Dermatomyositis (ADM) , by Region USD Million (2020-2025)
  • Table 134. Dermatomyositis Treatment Hypomyopathic Dermatomyositis (HDM) , by Region USD Million (2020-2025)
  • Table 135. Dermatomyositis Treatment Other , by Region USD Million (2020-2025)
  • Table 136. Dermatomyositis Treatment: by Age Group(USD Million)
  • Table 137. Dermatomyositis Treatment Children , by Region USD Million (2020-2025)
  • Table 138. Dermatomyositis Treatment Adults , by Region USD Million (2020-2025)
  • Table 139. Dermatomyositis Treatment: by Medication Type(USD Million)
  • Table 140. Dermatomyositis Treatment Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent) , by Region USD Million (2020-2025)
  • Table 141. Dermatomyositis Treatment Non-Pharmacotherapy (General Therapeutic Measures, Surgery) , by Region USD Million (2020-2025)
  • Table 142. Dermatomyositis Treatment: by End User(USD Million)
  • Table 143. Dermatomyositis Treatment Hospitals , by Region USD Million (2020-2025)
  • Table 144. Dermatomyositis Treatment Research & Development Institutes , by Region USD Million (2020-2025)
  • Table 145. Dermatomyositis Treatment Other , by Region USD Million (2020-2025)
  • Table 146. South America Dermatomyositis Treatment, by Country USD Million (2020-2025)
  • Table 147. South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 148. South America Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 149. South America Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 150. South America Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 151. Brazil Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 152. Brazil Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 153. Brazil Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 154. Brazil Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 155. Argentina Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 156. Argentina Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 157. Argentina Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 158. Argentina Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 159. Rest of South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 160. Rest of South America Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 161. Rest of South America Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 162. Rest of South America Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 163. Asia Pacific Dermatomyositis Treatment, by Country USD Million (2020-2025)
  • Table 164. Asia Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 165. Asia Pacific Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 166. Asia Pacific Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 167. Asia Pacific Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 168. China Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 169. China Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 170. China Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 171. China Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 172. Japan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 173. Japan Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 174. Japan Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 175. Japan Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 176. India Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 177. India Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 178. India Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 179. India Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 180. South Korea Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 181. South Korea Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 182. South Korea Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 183. South Korea Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 184. Taiwan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 185. Taiwan Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 186. Taiwan Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 187. Taiwan Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 188. Australia Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 189. Australia Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 190. Australia Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 191. Australia Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 192. Rest of Asia-Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 193. Rest of Asia-Pacific Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 194. Rest of Asia-Pacific Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 195. Rest of Asia-Pacific Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 196. Europe Dermatomyositis Treatment, by Country USD Million (2020-2025)
  • Table 197. Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 198. Europe Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 199. Europe Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 200. Europe Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 201. Germany Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 202. Germany Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 203. Germany Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 204. Germany Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 205. France Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 206. France Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 207. France Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 208. France Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 209. Italy Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 210. Italy Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 211. Italy Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 212. Italy Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 213. United Kingdom Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 214. United Kingdom Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 215. United Kingdom Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 216. United Kingdom Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 217. Netherlands Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 218. Netherlands Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 219. Netherlands Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 220. Netherlands Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 221. Rest of Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 222. Rest of Europe Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 223. Rest of Europe Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 224. Rest of Europe Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 225. MEA Dermatomyositis Treatment, by Country USD Million (2020-2025)
  • Table 226. MEA Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 227. MEA Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 228. MEA Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 229. MEA Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 230. Middle East Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 231. Middle East Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 232. Middle East Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 233. Middle East Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 234. Africa Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 235. Africa Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 236. Africa Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 237. Africa Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 238. North America Dermatomyositis Treatment, by Country USD Million (2020-2025)
  • Table 239. North America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 240. North America Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 241. North America Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 242. North America Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 243. United States Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 244. United States Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 245. United States Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 246. United States Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 247. Canada Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 248. Canada Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 249. Canada Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 250. Canada Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 251. Mexico Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2020-2025)
  • Table 252. Mexico Dermatomyositis Treatment, by Age Group USD Million (2020-2025)
  • Table 253. Mexico Dermatomyositis Treatment, by Medication Type USD Million (2020-2025)
  • Table 254. Mexico Dermatomyositis Treatment, by End User USD Million (2020-2025)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dermatomyositis Treatment: by Dermatomyositis Type USD Million (2014-2019)
  • Figure 5. Global Dermatomyositis Treatment: by Age Group USD Million (2014-2019)
  • Figure 6. Global Dermatomyositis Treatment: by Medication Type USD Million (2014-2019)
  • Figure 7. Global Dermatomyositis Treatment: by End User USD Million (2014-2019)
  • Figure 8. South America Dermatomyositis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Dermatomyositis Treatment Share (%), by Country
  • Figure 10. Europe Dermatomyositis Treatment Share (%), by Country
  • Figure 11. MEA Dermatomyositis Treatment Share (%), by Country
  • Figure 12. North America Dermatomyositis Treatment Share (%), by Country
  • Figure 13. Global Dermatomyositis Treatment share by Players 2019 (%)
  • Figure 14. Global Dermatomyositis Treatment share by Players (Top 3) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Ranbaxy Laboratories Limited (India) Revenue, Net Income and Gross profit
  • Figure 17. Ranbaxy Laboratories Limited (India) Revenue: by Geography 2019
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 20. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 22. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 23. Cipla Limited (India) Revenue: by Geography 2019
  • Figure 24. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 26. Corbus Pharmaceuticals Holdings, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Corbus Pharmaceuticals Holdings, Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Global Dermatomyositis Treatment: by Dermatomyositis Type USD Million (2020-2025)
  • Figure 29. Global Dermatomyositis Treatment: by Age Group USD Million (2020-2025)
  • Figure 30. Global Dermatomyositis Treatment: by Medication Type USD Million (2020-2025)
  • Figure 31. Global Dermatomyositis Treatment: by End User USD Million (2020-2025)
  • Figure 32. South America Dermatomyositis Treatment Share (%), by Country
  • Figure 33. Asia Pacific Dermatomyositis Treatment Share (%), by Country
  • Figure 34. Europe Dermatomyositis Treatment Share (%), by Country
  • Figure 35. MEA Dermatomyositis Treatment Share (%), by Country
  • Figure 36. North America Dermatomyositis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Ranbaxy Laboratories Limited (India)
  • Abbott Laboratories (United States)
  • Sanofi S.A. (France)
  • Cipla Limited (India)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Corbus Pharmaceuticals Holdings, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation